Secretome Therapeutics, a Dallas-based biotechnology company developing first-in-class therapeutics from neonatal mesenchymal stem cells, has appointed Margot Connor to its board of directors and announced the appointment of its clinical advisory board composed of world-class clinicians and researchers in the field of heart failure.
“I have been fortunate to be part of the stem cell-based therapy evolution, and I believe secretomes are a true breakthrough in this extraordinary field,” Connor said in a statement. “Secretome Therapeutics’ team, vision, and groundbreaking products have the potential to revolutionize treatment for a wide range of chronic, inflammatory diseases, and I am thrilled to join the company’s Board.”
The new Clinical Advisory Board members include:
- Javed Butler, MD, President, Baylor, Scott and White Research Institute and Member, FDA Cardio-Renal Advisory Committee
- Barry Greenberg, MD, Director of the Advanced Heart Failure Treatment Program, and Distinguished Professor of Medicine at U.C. San Diego
- Steven Lipshultz, MD, Professor of Pediatrics at the University at Buffalo Jacobs School of Medicine & Biomedical Sciences and Principal Investigator of the North American Pediatric Cardiomyopathy Registry
- Arshed Quyyumi, MD, Professor of Medicine, Director of the Emory Clinical Cardiovascular Research Institute
- Sanjiv Shah, MD, Professor of Medicine, Founder and Director of the Heart Failure with Preserved Ejection Fraction (HFpEF) Program at the Northwestern University Feinberg School of Medicine
“Margot’s unparalleled experience in the manufacturing and development of cell-based therapies, and her success building organizations from the ground up strengthen our ability to realize the enormous potential of our pipeline,” Vinny Jindal, Secretome Therapeutics’ president and CEO, said in a statement. “In addition, our CAB includes preeminent physicians who are among the foremost thought leaders in the field of heart failure. Their guidance will be invaluable as we move STM-01 into clinical studies for HFpEF and dilated cardiomyopathy.”
Connor brings more that 30 years of experience in the healthcare and life science industries, and has executive level expertise in leadership, business growth, operational execution, corporate development, strategic planning, and M&A.
Most recently, she was CEO and board member of RoosterBio Inc., where she joined as a founding team member in 2015 and led multiple rounds of investment funding.
During her career, Connor has been involved in more 20 M&A transactions valued at over $1 billion. She has held various senior leadership roles at companies including Lonza, Unilever, FMC, and Chr. Hansen.
Secretome Therapeutics is developing a platform of first-in-class therapeutics derived from neonatal mesenchymal stem cells (nMSC) for the treatment of underserved diseases.
Its lead product, STM-01, is in development for adult and pediatric forms of heart failure, and the company’s pipeline includes novel secretomes for neurodegenerative and dermatological diseases.
Get on the list.
Dallas Innovates, every day.
Sign up to keep your eye on what’s new and next in Dallas-Fort Worth, every day.